Haemonetics share price today

Haemonetics Corporation's share price was $127.42 at the close on 4 November 2026. It has been rising for 22 weeks. That is 60.5% above its average price over the last 200 trading days. In the last 52 weeks it traded between $54 and $127, and at that close it was at the high of that range.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Haemonetics Corporation is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 23 weeks in a row.

Over the last 10 years the share price moved +322% while the S&P 500 moved +261%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Haemonetics Corporation pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes.

Haemonetics is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list.

Haemonetics Corporation earned $33.0 M of net profit in the Jun 2026 quarter, −3.0% on the same quarter a year earlier. Full-year FY26 profit was $97.3 M. Over 4 years profit has grown 22.4% a year on average. That is 9.7% of the quarter's revenue. The same quarter a year earlier earned $34.0 M.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

1 of the last 12 reported quarters were loss-making.

For the full year, FY26 profit was $97.3 M (−42.0% on the year before).

Why profit moved: revenue changed +5.6% on a year earlier and the margin moved +0.0 percentage points. Sales did the work, and the margin was about flat.

On average over the last four quarters, profit changed −26.0% and revenue +0.6%. Profit is growing slower than sales: rising costs are taking part of the growth.

Haemonetics Corporation reported $339 M of revenue in the Jun 2026 quarter, +5.6% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 4 years it has grown 7.7% a year on average. The last full year, FY26, came in at $1.3 B.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to $1.4 B.

FY26 revenue was $1.3 B, −2.0% on the year before.

Recent pace: the last four quarters grew +0.6% on average, against 7.7% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +0.4%, against +0.7% a year over the last 8 quarters (stabilising); profit over the last 12 months grew −41.1%, against −8.5% a year (rolling over).

Haemonetics Corporation's operating margin was 17.9% in the Jun 2026 quarter, about the same as the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 5 years it has been between 10.6% and 18.9%. The latest quarter is within that range.

Operating margin is what is left from every $100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

In the latest quarter it moved +0.0 percentage points on the same quarter a year ago.

Why the margin moved: operating margin changed +0.0 percentage points on the year while gross margin changed −0.5 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold.

Over the last 3 years, 172% of Haemonetics Corporation's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in $293 M of operating cash against $97.3 M of profit. After $32.8 M of spending on assets, $260 M was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason.

What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building.

Haemonetics Corporation does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $110 M on assets over the last 3 years. Averaged over those years that is 2.8% of FY26 revenue a year.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn.

Spending on assets: $110 M over the last 3 years.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Haemonetics Corporation's P/E is 61.9×, near the high end of its own history: higher than 95% of past readings. Its usual P/E (the middle reading) is 34.6×, over 4.6 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many dollars the market pays for each dollar of yearly profit.